A2-Ai
Home
LeadershipBlogCareersGet in touch
Home
LeadershipBlogCareersGet in touch
All posts Category / updates

Categories

blogcase studiesnewsproductsresearch spotlightsservicestoolingupdates

Tags

2025ADaMADMEAgingAIAnimal Modelsanimal testingAnnualapproval processbetween-subject variabilityCardiac Safetycdisc
RSS See all filters
newest
updates

A Year of Science at A2-Ai: Reflections from 2025

Meg Gonsalves December 26, 2025
A MESSAGE FROM OUR CEO
A2-Ai's 2025 Year in Review
Time flew and it is already time to reflect the year 2025. For A2-Ai, this year was defined by pushing boundaries, deepening collaborative partnerships, accelerating technological innovation, and, most importantly, letting our people and culture lead the way.
We supported another year of growing submission volume and regulatory engagement for our clients in the U.S. and across our expanding international footprint. Much of this success stemmed from the technology our team has developed: AI-enabled tools, packages, and products that streamline report generation, enhance collaboration, and enable quality control at scale. I'm especially proud to share that all submissions were built using R-based reproducible workflows for authoring and version control on our A2-Ai Cloud platform, along with a 100% agency acceptance rate.
Beyond submissions and drug development, we reached an exciting milestone: A2-Ai technologies are now fully implemented across organizations ranging from early preclinical pharma to some of the largest pharmaceutical enterprises in the world, as well as other CROs. But the momentum didn't stop there. We expanded into new industries - including federal, energy, beverage, legal, and more - reinforcing something we believe deeply: when you lead with a solutions-first mindset, impact follows. This progress supports our vision of being more than a life-sciences leader; becoming a solutions company built to empower people across industries to do more, faster, and with greater confidence.
Most importantly, A2-Ai continues to grow through the strength of our collaborators, teams and individuals who refuse to accept the status quo in their pursuit of better outcomes for the people who need them most. That shared drive is at the heart of why we do what we do. This year, traveling to conferences like Posit:Conf, ACoP, and ASCPT gave us the chance to meet so many of you in person who make these industries so great. These events helped us deepen our relationships, speak openly about what's working, and stay honest about where we can keep improving - while always staying anchored to our mission.
Looking ahead to the new year, we're energized to see how our unique blend of people, culture, and technology helps to transform the development of new therapies and the delivery of solutions to those who need them. Thank you to everyone who has joined us so far on our journey. We are just getting started and can't wait to keep building together.
Wishing everyone a prosperous and impactful 2026.
- Sunny
updates

A Message from Sunny Chapel: 2025 Year in Review

Eric Storms December 16, 2025

Links

HomeLeadershipBlogCareersContact

Solutions

A2-Ai CloudAlexandriaPRISMSage AI

Science Services

EducationFDA Project OptimusClinical PharmacologyPharmacometricsPreclinical Support

Technology Services

Technology

Calculators

Exposure-Response ThresholdsMulti-compartment PK Parameter Conversion

Resources

Attributions
A2-Ai

2723 S. State Street
Suite 310
Ann Arbor, MI 48104

© 2026 A2-Ai LLC. All rights reserved.